Sojourn (sevoflurane) NDC 66794-012

NDC codes

FDA NDC Directory

Product NDC (as listed)66794-012Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66794-0012Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
66794-012-25	66794001225	250 mL in 1 BOTTLE, GLASS (66794-012-25)Marketed from Apr 13, 2010

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sojourn
Generic name (nonproprietary): sevoflurane
Active ingredients: Sevoflurane — 1 mL/mL
Dosage form: Liquid
Route: Respiratory (Inhalation)
Labeler: Piramal Critical Care Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077867
Marketing start: Apr 13, 2010
Listing expires: Dec 31, 2026
Other FDA classes: General Anesthesia (Physiologic effect)
Identifiers: Product ID 66794-012_44ded994-d330-0d67-e063-6394a90a92dbSPL ID 44ded994-d330-0d67-e063-6394a90a92dbSPL set ID fedfd1db-7e32-44b2-89e9-7bb00ee6810dRxCUI 200243, 997625UNII 38LVP0K73A
Pharmacologic class: General Anesthetic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N466794001225 followed by a unit qualifier and the quantity

Package 66794-0012-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 1, 2025.

Indications (excerpt from the label)

INDICATIONS & USAGE Sojourn ® (sevoflurane, USP) is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sojourn ® (sevoflurane, USP) should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, USP should be used.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077867

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077867
Product	Strength	Form · route	Labeler	Product NDC
Sevoflurane	Sevoflurane 1 mL/mL	LiquidRespiratory (Inhalation)	Bryant Ranch Prepack	72162-2245
Sevoflurane	Sevoflurane 1 mL/mL	LiquidRespiratory (Inhalation)	Piramal Critical Care Inc	66794-015
Sevoflurane	Sevoflurane 1 mL/mL	LiquidRespiratory (Inhalation)	Piramal Critical Care Inc	66794-022